Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Research & Development: 2009-2024

Historic Research & Development for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $12.5 million.

  • Lineage Cell Therapeutics' Research & Development rose 3.15% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 0.32%. This contributed to the annual value of $12.5 million for FY2024, which is 20.59% down from last year.
  • Lineage Cell Therapeutics' Research & Development amounted to $12.5 million in FY2024, which was down 20.59% from $15.7 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Research & Development ranged from a high of $33.9 million in FY2021 and a low of $12.3 million during FY2020.
  • Over the past 3 years, Lineage Cell Therapeutics' median Research & Development value was $14.0 million (recorded in 2022), while the average stood at $14.1 million.
  • In the last 5 years, Lineage Cell Therapeutics' Research & Development spiked by 175.34% in 2021 and then plummeted by 58.76% in 2022.
  • Lineage Cell Therapeutics' Research & Development (Yearly) stood at $12.3 million in 2020, then soared by 175.34% to $33.9 million in 2021, then slumped by 58.76% to $14.0 million in 2022, then grew by 12.28% to $15.7 million in 2023, then dropped by 20.59% to $12.5 million in 2024.